Supernus Pharma (SUPN) Defended at SunTrust: 'Buy On Weakness'
Tweet
Share
E-mailGet Alerts SUPN Hot Sheet
Price: $44.48 --0%
Rating Summary:
9 Buy, 3 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 7 | Down: 14 | New: 26
Rating Summary:
9 Buy, 3 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 7 | Down: 14 | New: 26
Join SI Premium – FREE
SunTrust Robinson Humphrey maintains Buy on Supernus Pharmaceuticals (NASDAQ: SUPN) price target of $61.00.
Analyst Jon Boris says Tokendi XR launch progress and pipeline progress are the focal points.
For an analyst ratings summary and ratings history on Supernus Pharmaceuticals click here. For more ratings news on Supernus Pharmaceuticals click here.
Shares of Supernus Pharmaceuticals closed at $41.10 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Natera (NTRA) PT Raised to $270 at BTIG
- Goldman Sachs Starts Lovisa Holdings Ltd (LOV:AU) at Neutral
- Southwest (LUV) PT Raised to $61 at UBS Ahead of Q2 Print
Create E-mail Alert Related Categories
Analyst Comments, Hot CommentsRelated Entities
SunTrust Robinson HumphreySign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
